These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29489517)

  • 1. Topical Interferon Alpha-2b Induced Reactive Lymphoid Hyperplasia Masquerading as Orbital Extension of Ocular Surface Squamous Neoplasia.
    Lee GA; Hess L; Glasson WJ; Whitehead K
    Cornea; 2018 Jun; 37(6):796-798. PubMed ID: 29489517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification.
    Shah SU; Kaliki S; Kim HJ; Lally SE; Shields JA; Shields CL
    Arch Ophthalmol; 2012 Feb; 130(2):159-64. PubMed ID: 22332208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of conjunctival and corneal epithelial neoplasia with retinoic acid and topical interferon alfa-2b: long-term follow-up.
    Krilis M; Tsang H; Coroneo M
    Ophthalmology; 2012 Oct; 119(10):1969-73. PubMed ID: 22704834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b.
    Boehm MD; Huang AJ
    Ophthalmology; 2004 Sep; 111(9):1755-61. PubMed ID: 15350333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical Interferon α-2b as a Single Therapy for Primary Ocular Surface Squamous Neoplasia.
    Kusumesh R; Ambastha A; Sinha B; Kumar R
    Asia Pac J Ophthalmol (Phila); 2015; 4(5):279-82. PubMed ID: 26176194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical interferon alfa-2b for the treatment of recalcitrant ocular surface squamous neoplasia.
    Holcombe DJ; Lee GA
    Am J Ophthalmol; 2006 Oct; 142(4):568-71. PubMed ID: 17011846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b.
    Schechter BA; Koreishi AF; Karp CL; Feuer W
    Ophthalmology; 2008 Aug; 115(8):1291-6, 1296.e1. PubMed ID: 18187195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppression as a Possible Risk Factor for Interferon Nonresponse in Ocular Surface Squamous Neoplasia.
    Ashkenazy N; Karp CL; Wang G; Acosta CM; Galor A
    Cornea; 2017 Apr; 36(4):506-510. PubMed ID: 28129301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia.
    Sturges A; Butt AL; Lai JE; Chodosh J
    Ophthalmology; 2008 Aug; 115(8):1297-302, 1302.e1. PubMed ID: 18294690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant treatment or primary topical monotherapy for ocular surface squamous neoplasia: a systematic review.
    Viani GA; Fendi LI
    Arq Bras Oftalmol; 2017; 80(2):131-136. PubMed ID: 28591290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia.
    Venkateswaran N; Mercado C; Galor A; Karp CL
    Am J Ophthalmol; 2019 Mar; 199():216-222. PubMed ID: 30471241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b.
    Besley J; Pappalardo J; Lee GA; Hirst LW; Vincent SJ
    Am J Ophthalmol; 2014 Feb; 157(2):287-293.e2. PubMed ID: 24184223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
    Schechter BA; Schrier A; Nagler RS; Smith EF; Velasquez GE
    Cornea; 2002 Jan; 21(1):6-11. PubMed ID: 11805499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Confocal biomicroscopy of corneal intraepithelial neoplasia regression following interferon alpha 2b treatment.
    Gabison EE; Labbé A; Brignole-Baudouin F; Nourry H; Putterman M; Malecaze F; Hoang-Xuan T; Baudouin C
    Br J Ophthalmol; 2010 Jan; 94(1):134-5. PubMed ID: 20385531
    [No Abstract]   [Full Text] [Related]  

  • 15. Topical chemotherapy for giant ocular surface squamous neoplasia of the conjunctiva and cornea: Is surgery necessary?
    Chaugule SS; Park J; Finger PT
    Indian J Ophthalmol; 2018 Jan; 66(1):55-60. PubMed ID: 29283124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Pegylated Interferon and Mitomycin C on Ocular Surface Squamous Neoplasia in Xeroderma Pigmentosum: A Case Series.
    Dirar QS; Musalem HM; Al-Hazzaa SAF; Al Zoba AA; Almalki AA
    Am J Case Rep; 2020 Apr; 21():e921301. PubMed ID: 32251268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical medical therapies for ocular surface tumors.
    Poothullil AM; Colby KA
    Semin Ophthalmol; 2006; 21(3):161-9. PubMed ID: 16912014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The regression time of ocular surface squamous neoplasia using topical interferon alfa-2b does not depend on the initial tumor size.
    Vilaltella M; Huerva V
    Arq Bras Oftalmol; 2021; 85(2):109-114. PubMed ID: 34431893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia.
    Vann RR; Karp CL
    Ophthalmology; 1999 Jan; 106(1):91-7. PubMed ID: 9917787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
    Karp CL; Moore JK; Rosa RH
    Ophthalmology; 2001 Jun; 108(6):1093-8. PubMed ID: 11382635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.